Tue Apr 22, 2014 12:57pm EDT
<span id="articleText"/>(Reuters) - The U.S. Food and Drug Administration proposed on Tuesday a more collaborative approach aimed at speeding up marketing approval for high-risk medical devices intended to treat patients with serious conditions that have no other treatment options.
<span id="midArticle_0"/>The proposed Expedited Access Premarket Approval Application program would feature earlier and more frequent interactions between companies and FDA staff. (r.reuters.com/kaw68v)
<span id="midArticle_1"/>The proposal is a response to criticisms by policymakers, patient groups and the industry that the FDA's process for approving medical devices is inefficient and slow, thereby denying patients access to new, helpful products.
<span id="midArticle_2"/>The program is not a new pathway to market, the FDA said, but rather a change in approach aimed at reducing the time it takes to develop a product and get it to market.
<span id="midArticle_3"/>A device can be eligible for the program if it features breakthrough technology with significant benefits over existing products.
<span id="midArticle_4"/>The FDA issued a rule in September that requires device manufacturers to put unique codes on their products that will allow regulators to track and monitor them in the event of a safety problem.
<span id="midArticle_5"/>Also in September, the agency issued final rules on mobile medical apps, saying it would only regulate apps that transform smartphones into devices that the agency currently regulates, such as electrocardiography machines that can determine whether a patient is having a heart attack.
<span id="midArticle_6"/>The FDA also published on Tuesday draft guidance on when data can be collected after a product's approval and what actions the agency can take if approval conditions such as postmarket data collection are not met. The regulator is now seeking public comment on the proposals.
<span id="midArticle_7"/>(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)
<span id="midArticle_8"/>
<span id="articleText"/>(Reuters) - The U.S. Food and Drug Administration proposed on Tuesday a more collaborative approach aimed at speeding up marketing approval for high-risk medical devices intended to treat patients with serious conditions that have no other treatment options.
<span id="midArticle_0"/>The proposed Expedited Access Premarket Approval Application program would feature earlier and more frequent interactions between companies and FDA staff. (r.reuters.com/kaw68v)
<span id="midArticle_1"/>The proposal is a response to criticisms by policymakers, patient groups and the industry that the FDA's process for approving medical devices is inefficient and slow, thereby denying patients access to new, helpful products.
<span id="midArticle_2"/>The program is not a new pathway to market, the FDA said, but rather a change in approach aimed at reducing the time it takes to develop a product and get it to market.
<span id="midArticle_3"/>A device can be eligible for the program if it features breakthrough technology with significant benefits over existing products.
<span id="midArticle_4"/>The FDA issued a rule in September that requires device manufacturers to put unique codes on their products that will allow regulators to track and monitor them in the event of a safety problem.
<span id="midArticle_5"/>Also in September, the agency issued final rules on mobile medical apps, saying it would only regulate apps that transform smartphones into devices that the agency currently regulates, such as electrocardiography machines that can determine whether a patient is having a heart attack.
<span id="midArticle_6"/>The FDA also published on Tuesday draft guidance on when data can be collected after a product's approval and what actions the agency can take if approval conditions such as postmarket data collection are not met. The regulator is now seeking public comment on the proposals.
<span id="midArticle_7"/>(Reporting by Esha Dey in Bangalore; Editing by Maju Samuel)
<span id="midArticle_8"/>
- Link this
- Share this
- Digg this
- Reprints
via Smart Health Shop Forum http://ift.tt/1hdVqHU
No comments:
Post a Comment